# A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

> **NCT01283516** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 304 (actual)

## Conditions studied

- Tumors Characterized by Genetic Abnormalities of ALK

## Interventions

- **DRUG:** LDK378

## Key facts

- **NCT ID:** NCT01283516
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-24
- **Primary completion:** 2016-05-03
- **Final completion:** 2016-05-03
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283516, "A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01283516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*